A Study Evaluating The Effectiveness Of Lanreotide Autogel (Somatuline Autogel) As An Alternative Regimen To Treat Patients Who Are Unresponsive To Treatment With Octreotide-LAR

Trial Profile

A Study Evaluating The Effectiveness Of Lanreotide Autogel (Somatuline Autogel) As An Alternative Regimen To Treat Patients Who Are Unresponsive To Treatment With Octreotide-LAR

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2017 New trial record
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top